Drug intelligence / Profile preview

Lactobacillus acidophilus SLAM_LAA02

Development stage: Preclinical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus acidophilus SLAM_LAA02 is a novel probiotic strain isolated from human infants, currently being investigated for its neuroprotective and immunomodulatory properties in the context of Parkinson's disease (PD). Preclinical studies in *Caenorhabditis elegans* and rotenone-induced mouse models demonstrate that SLAM_LAA02 administration can ameliorate motor dysfunction, restore gut microbial diversity, and enhance intestinal barrier integrity. Mechanistically, the strain modulates the microbiota-gut-brain axis, leading to a reduction in alpha-synuclein expression and aggregation, alongside the upregulation of neuroprotective factors such as brain-derived neurotrophic factor (BDNF) and the modulation of neuroinflammatory signaling.

Other names: L. acidophilus SLAM_LAA02

Targets

SNCA (Alpha-synuclein)BDNF (Brain-derived neurotrophic factor)

Beyond the preview

Go deeper on Lactobacillus acidophilus SLAM_LAA02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus acidophilus SLAM_LAA02.

Explore the full profile